Physician profile
Edith Nemeth
NPI 1841391133
$2,187.04
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2021: $55.82 · 2022: $498 · 2023: $1,204 · 2024: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $329.70 | 2019-2023 | |
| Novo Nordisk INC | $257.52 | 2019-2024 | Wegovy, Saxenda |
| Abbvie INC. | $253.52 | 2022-2023 | |
| Glaxosmithkline, LLC. | $223.45 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $217.96 | 2022-2023 | Mounjaro, Reyvow, Emgality |
| Astrazeneca Pharmaceuticals LP | $138.44 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $92.32 | 2022 | |
| Exact Sciences Corporation | $90.16 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $83.16 | 2022-2023 | Quviviq |
| Dexcom, INC. | $61.66 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $54.12 | 2024 | Voquezna |
| Amgen INC. | $47.95 | 2019-2024 | Repatha, Evenity, Prolia |
| Sanofi Pasteur INC. | $44.79 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $37.99 | 2021 | |
| Neurelis, INC. | $35.98 | 2023 | Valtoco |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.00 | 2022-2023 | Stiolto Respimat |
| Astellas Pharma US INC | $31.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.00 | 2022 | |
| Merck Sharp & Dohme LLC | $22.46 | 2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Abbott Laboratories | $20.97 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $20.95 | 2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $18.85 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $17.60 | 2022 | |
| Orexo US, INC. | $15.38 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Nemeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.